LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan

Stock News03-27

LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million yuan, representing a year-on-year increase of 55.7%. The annual net loss was approximately 211 million yuan, which is a decrease of 29.8% compared to the previous year.

According to the announcement, the revenue was derived from an upfront and recent milestone payment of 177.3 million yuan received under a licensing agreement with Dianthus Therapeutics for LBL-047. The increase in R&D costs was primarily attributed to several factors: (i) increased expenses related to CMC development milestones, mainly associated with preparations for the Biologics License Application (BLA) submission for LBL-024; (ii) higher clinical development expenses due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034; and (iii) increased preclinical expenses as the company advances multiple pipeline assets into the Investigational New Drug (IND) preparation phase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124822191?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124822191","market":"fut","top_or_hot":-1,"title":"LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million yuan, representing a year-on-year increase of 55.7%. The annual net loss was approximately 211 million yuan, which is a decrease of 29.8% compared to the previous year.</p>\n<p>According to the announcement, the revenue was derived from an upfront and recent milestone payment of 177.3 million yuan received under a licensing agreement with Dianthus Therapeutics for LBL-047. The increase in R&D costs was primarily attributed to several factors: (i) increased expenses related to CMC development milestones, mainly associated with preparations for the Biologics License Application (BLA) submission for LBL-024; (ii) higher clinical development expenses due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034; and (iii) increased preclinical expenses as the company advances multiple pipeline assets into the Investigational New Drug (IND) preparation phase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B Reports 2025 Financial Results: Net Loss Narrows to 211 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-27 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million yuan, representing a year-on-year increase of 55.7%. The annual net loss was approximately 211 million yuan, which is a decrease of 29.8% compared to the previous year.</p>\n<p>According to the announcement, the revenue was derived from an upfront and recent milestone payment of 177.3 million yuan received under a licensing agreement with Dianthus Therapeutics for LBL-047. The increase in R&D costs was primarily attributed to several factors: (i) increased expenses related to CMC development milestones, mainly associated with preparations for the Biologics License Application (BLA) submission for LBL-024; (ii) higher clinical development expenses due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034; and (iii) increased preclinical expenses as the company advances multiple pipeline assets into the Investigational New Drug (IND) preparation phase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252152.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","start_time":0,"source_url":"","article_id":"1124822191","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124822191","pubTimestamp":1774602704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK1161":"生物科技","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","09887":"维立志博-B"},"translate_title":"LEADS BIOLABS-B报告2025年财务业绩：净亏损收窄至2.11亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) announced its financial results for the year 2025. The company reported revenue of approximately 177 million yuan. Research and development costs reached about 289 million yuan, representing a year-on-year increase of 55.7%. The annual net loss was approximately 211 million yuan, which is a decrease of 29.8% compared to the previous year.\nAccording to the announcement, the revenue was derived from an upfront and recent milestone payment of 177.3 million yuan received under a licensing agreement with Dianthus Therapeutics for LBL-047. The increase in R&D costs was primarily attributed to several factors: (i) increased expenses related to CMC development milestones, mainly associated with preparations for the Biologics License Application (BLA) submission for LBL-024; (ii) higher clinical development expenses due to accelerated patient enrollment and clinical progress for LBL-024 and LBL-034; and (iii) increased preclinical expenses as the company advances multiple pipeline assets into the Investigational New Drug (IND) preparation phase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124822191","isCrawlerRequest":true}